Prevalence and impact of hypereosinophilia in severe asthma treated by dupilumab: an observational analysis

S. Everaerts (Leuven, Belgium), B. Hilvering (Amsterdam, Netherlands), E. Weersink (Amsterdam, Netherlands)

Source: International Congress 2022 – Recent advances in biological treatments for asthma

Session: Recent advances in biological treatments for asthma
Session type: Oral Presentation
Number: 3671

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Everaerts (Leuven, Belgium), B. Hilvering (Amsterdam, Netherlands), E. Weersink (Amsterdam, Netherlands). Prevalence and impact of hypereosinophilia in severe asthma treated by dupilumab: an observational analysis. 3671

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.